Regulation of TMEFF1 on proliferation of neuroblastoma cell lines

doi:10.16352/j.issn.1001-6325.2024.05.0637

Abstract

Abstract: Objective To investigate the regulatory effects of transmembrane protein with EGF-like and two follistatin-like domain 1(TMEFF1/tomoregulin 1) on the proliferation and migration of neuroblastoma (NB) cell line SN-K-BE(2). Methods TMEFF1 mRNA in neuroblastoma cell lines SN-K-BE(2), IMR32, SK-N-SH, SK-N-AS and normal cell lines MCF10A and hTERT RPE-1 was detected by RT-qPCR. Small interfering RNA (siRNA) was used to construct transient knockdown TMEFF1 normal and SN-K-BE (2) NB cell lines. The effect of transient knockdown of TMEFF1 mRNA was examined by RT-qPCR. After transfection of SN-K-BE (2) cells with siRNA, cell proliferation was detected by colony-forming unit assay and real-time cell analysis (RTCA). The positive rate of Ki-67 cells was determined by immunofluorescence staining. CellTiter-Glo (CTG) was used to detect cell activity. Stable knockdown of TMEFF1 was performed in SK-N-BE(2) cells by short hairpin RNA (shRNA) lentiviral infection, the stable outcomes of TMEFF1 was also detected by RT-qPCR. Cell proliferation was detected by coloning formation, RTCA and CTG. In addition, the positive rate of Ki-67 cells was detected by immunofluorescence,the cell mobility was measured by cell scratch assay. Results Compared with normal cell lines, the expression of TMEFF1 in NB cell lines was significantly higher (P＜0.001). Transient or stable knockdown of TMEFF1 had no significant effect on the proliferation of normal cell lines. However, by knocking down TMEFF1 decreased cell proliferation of SN-K-BE (2) cells as showen RTCA and colony-forming unit assay (P＜0.05). Immunofluorescence results showed that the rate of Ki-67 positive cells was reduced (P＜0.001). CTG results showed that the cell activity was decreased(P＜0.01). Cell scratch assay also showed that the cell migration ratio in the knockdown group was significantly lower than that of control group (P＜0.01). Conclusions TMEFF1 is a protein specifically highly expressed in neuroblastoma. TMEFF1 knockdown has no effect on normal cell lines, but significantly inhibited the proliferation and migration of NB cells, suggesting that TMEFF1 may play an important role in the occurrence and development of neuroblastoma, and so may be a potential target for NB targeting therapy.

Key words: neuroblastoma, transmembrane protein with EGF-like and two follistatin-like domain 1(TMEFF1/tomoregulin 1), cell proliferation, cell migration

CLC Number:

R739.43

JIA Anna, GUO Jinxin, ZHANG Xuan, ZHAN Shijia, YU Yongbo, GUO Yongli, CHANG Yan. Regulation of TMEFF1 on proliferation of neuroblastoma cell lines[J]. Basic & Clinical Medicine, 2024, 44(5): 637-644.

References

[1] Maris JM.Recent advances in neuroblastoma[J]. N Engl J Med, 2010, 362: 2202-2211.
[2] Skertich NJ, Chu F, Tarhoni IAM, et al. Expression of immunomodulatory checkpoint molecules in drug-resistant neuroblastoma: An Exploratory Study[J]. Cancers, 2022, 14: 751-763.
[3] Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological approach to risk stratification and treatment[J]. Cell Tissue Res, 2018, 372: 195-209.
[4] Lin KS, Uemura S, Thwin KKM, et al. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood[J]. Transl Oncol, 2021, 14. doi:10.1016/j.tranon.2021.101019.
[5] Gery S, Yin D, Xie D, et al. TMEFF1 and brain tumors[J]. Oncogene, 2003, 22: 2723-2727.
[6] 朱丽丹,孔佩艳,张曦,等.蛋白芯片用于筛选急性髓系白血病患者血清标志物的初步研究[J].中国输血杂志,2013,26:110-115.
[7] Nie X, Liu C, Guo Q, et al. TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer[J]. Cancer Manag Res, 2019, 11: 839-855.
[8] Tian J, Yang L, Wang Z et al. miR503HG impeded ovarian cancer progression by interacting with SPI1 and preventing TMEFF1 transcription[J]. Aging, 2022, 14: 5390-5405.
[9] Nie X, Gao L, Zheng M, et al. Overexpression of TMEFF1 in endometrial carcinoma and the mechanism underlying its promotion of malignant behavior in cancer cells[J]. J Cancer, 2021, 12: 5772-5788.
[10] Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma[J]. Nat Genet, 2013, 45: 279-284.
[11] Markham, A. Naxitamab: first approval[J]. Drugs, 2021, 81: 291-296.
[12] Schumacher-Kuckelkorn R, Volland R, Gradehandt A, et al. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence[J]. Pediatr Blood Cancer, 2016, 64: 46-56.

[1]	YAO Anjun, CHEN Lingzi, JIN Huixian. Docosahexaenoic acid inhibits proliferation of human colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2024, 44(8): 1107-1112.
[2]	CAO Qingwen, QI Lin, YU Bo, TIAN Chenchen, YUAN Haining, WANG Yue. Salidroside promotes proliferation and migration of human vascular endothelial cell line EA.hy926 [J]. Basic & Clinical Medicine, 2024, 44(7): 925-930.
[3]	ZHANG Pengju, LI Jie, ZHANG Mengdi, SUN Shaoke, XU Yinzhe. KAT8 promotes the proliferation of colorectal cancer cell lines by enhancing METTL3 expression [J]. Basic & Clinical Medicine, 2024, 44(7): 931-939.
[4]	GAO Yinjie, TONG Anli. Mechanisms of cell death and proliferation of aldosterone-producing adenoma [J]. Basic & Clinical Medicine, 2024, 44(6): 758-762.
[5]	WANG Tingting, XIAO Ning, LIN Dianxin, DONG Haitao. Allicin inhibits the proliferation of oral cancer cells line CAL27 [J]. Basic & Clinical Medicine, 2024, 44(5): 673-676.
[6]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[7]	LU Kai, LU Jianju, GUO Wenli, HUANG Jianqi, LI Zhihua. lncRNA VIM-AS5 expression and its effect on proliferation and migration of human breast cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 447-453.
[8]	LI Na, LI Tao, YANG Dongli, YAO Yuan. Honokiol inhibits the proliferation of human adipose-derived mesenchymal stem cells [J]. Basic & Clinical Medicine, 2024, 44(4): 483-488.
[9]	JIA Anna, ZHAN Shijia, ZHANG Xuan, GUO Jinxin, YU Yongbo, GUO Yongli, CHANG Yan. Regulatory effect of C12ORF66 on viability of MYCN amplified high-risk neuroblastoma cells [J]. Basic & Clinical Medicine, 2024, 44(3): 288-294.
[10]	LIAO Zhencheng, YANG Siyi, WU Ping'an. Increased expression of m⁶A demethylase FTO inhibits the proliferation of nasopharyngeal carcinoma cells [J]. Basic & Clinical Medicine, 2024, 44(1): 57-62.
[11]	PAN Shan, LIN Kengqiang, CHEN Shuxing. Pemetrexed inhibits the proliferation of lung adenocarcinoma cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(9): 1359-1363.
[12]	LIANG Huiyong, WEI Qiuhui, DING Ya, PENG Xiaoqing, YAO Jing, SU Qijian. Cordycepin inhibits proliferation of human keratinocyte cell line HaCaT induced by TNF-α [J]. Basic & Clinical Medicine, 2023, 43(9): 1390-1393.
[13]	ZHANG Peibo, LI Yi. Total flavonoids of Hippophae rhamnoides L. inhibits proliferation of bladder cancer cell line T24 [J]. Basic & Clinical Medicine, 2023, 43(7): 1122-1126.
[14]	HOU Mengjie, ZHAO Na, HUANG Fuqiang, WANG Yanan, LIU Fangming. Apolipoprotein E negatively regulates Golgi membrane protein 73 to inhibit the proliferation of mouse liver cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(5): 762-770.
[15]	WANG Fangfang, CAO Huiyuan, WANG Jing, WANG Ning, HUANG Guoliang. Up-regulation of miR-200c-5p inhibits proliferation of human colorectal cancer cell line SW480 [J]. Basic & Clinical Medicine, 2023, 43(2): 241-245.